Assessment of the Effectiveness of TA Versus LEEP for Cervical Cancer Risk Reduction in WLHIV in Mozambique
Recruiting
N/A
Interventional Study
HIV Infections
HPV Infection
CIN 2/3
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 25 – 49
- Sex
- Female
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 4,844 (estimated)
- Sponsor
- Instituto Nacional de Saúde, Mozambique · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Given that WLWH are more likely to develop persistent HPV infection and CC, effective screening and the management and treatment of pre-cancerous cervical abnormalities is critical to decrease the global burden of cervical cancer. The vast majority of WLWH live in SSA, where resources are more constrained. Therefore, simple, affordable, and effective tools are needed for the prevention of cervical…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* ages 25-49 years;
* confirmed HIV infection;
* physically and mentally willing and able to participate in the study, and provide informed consent.
Exclusion Criteria:
* currently pregnant or \<6 weeks post-partum;
* had a hysterectomy and no longer have a cervix;
* a history…
Contacts